SCHEMBL1033097

SCHEMBL1033097

COc1cccc(-c2ccnc(NC3CCCCC3)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.57
EIF2AK2 P19525 1/20 0.57
DYRK1A Q13627 2/20 0.55
CLK4 Q9HAZ1 2/20 0.55
DYRK1B Q9Y463 1/20 0.55
MKNK2 Q9HBH9 2/20 0.53
CLK1 P49759 1/20 0.53
CCNA2 P20248 2/20 0.51
CDK2 P24941 2/20 0.51
MAPK3 P27361 1/20 0.51
MAPK1 P28482 1/20 0.51
PIK3CG P48736 4/20 0.51
PIK3CA P42336 3/20 0.51
PIK3CB P42338 3/20 0.51
CYP1A2 P05177 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
GALR2 O43603 1/20 0.51
GALR1 P47211 1/20 0.51
CDK1 P06493 3/20 0.50
CCNB1 P14635 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030948 0.87 CDK1 (0.49) MKNK1EIF2AK2MKNK2CCNA2CDK2
SCHEMBL1029832 0.87 CDK1 (0.49) MKNK1EIF2AK2MKNK2CCNA2CDK2
SCHEMBL1032945 0.87 CDK1 (0.49) MKNK1EIF2AK2MKNK2CCNA2CDK2
SCHEMBL1029427 0.87 ALOX5 (0.49) MKNK1EIF2AK2MKNK2CCNA2CDK2
SCHEMBL1034547 0.85 EIF2AK2 (0.58) EIF2AK2DYRK1ACLK4DYRK1BCLK1
SCHEMBL1032105 0.84 MAPT (0.46) MKNK1EIF2AK2DYRK1ACLK4DYRK1B
SCHEMBL1034404 0.83 CDK1 (0.51) MKNK1EIF2AK2MKNK2CCNA2CDK2
SCHEMBL1033626 0.81 CDK1 (0.53) MKNK2CCNA2CDK2MAPK1PIK3CA
SCHEMBL1028968 0.81 MAP4K4 (0.55) MKNK2CCNA2CDK2MAPK3MAPK1
SCHEMBL1030530 0.81 ADORA1 (0.59) EIF2AK2MKNK2CCNA2CDK2MAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO claimed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed